Actuate Therapeutics (ACTU) & Its Rivals Head to Head Comparison

Actuate Therapeutics (NASDAQ:ACTU) is one of 1,028 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Actuate Therapeutics to related companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Actuate Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	N/A	N/A
Actuate Therapeutics Competitors	-3,670.48%	-302.23%	-32.68%

Valuation & Earnings

This table compares Actuate Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	53.00
Actuate Therapeutics Competitors	$2.49 billion	$147.84 million	-5.00

Actuate Therapeutics’ peers have higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Actuate Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	0	0	0	0	N/A
Actuate Therapeutics Competitors	7112	19872	46326	1081	2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 63.07%. Given Actuate Therapeutics’ peers higher probable upside, analysts plainly believe Actuate Therapeutics has less favorable growth aspects than its peers.

Institutional & Insider Ownership

78.3% of Actuate Therapeutics shares are owned by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 19.9% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Actuate Therapeutics beats its peers on 6 of the 8 factors compared.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.